Equity Overview
Price & Market Data
Price: $1.16
Daily Change: +$0.05 / 4.31%
Daily Range: $1.09 - $1.17
Market Cap: $132,655,128
Daily Volume: 1,405,874
Performance Metrics
1 Week: 6.48%
1 Month: 3.60%
3 Months: 12.75%
6 Months: -17.86%
1 Year: -48.20%
YTD: -31.55%
Company Details
Employees: 181
Sector: Health technology
Industry: Biotechnology
Country:
Details
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.